Charles River Laboratories International (CRL) Operating Income (2016 - 2025)
Charles River Laboratories International has reported Operating Income over the past 17 years, most recently at -$283.4 million for Q4 2025.
- Quarterly results put Operating Income at -$283.4 million for Q4 2025, down 69.03% from a year ago — trailing twelve months through Dec 2025 was $25.2 million (down 88.93% YoY), and the annual figure for FY2025 was $25.2 million, down 88.93%.
- Operating Income for Q4 2025 was -$283.4 million at Charles River Laboratories International, down from $133.8 million in the prior quarter.
- Over the last five years, Operating Income for CRL hit a ceiling of $187.4 million in Q2 2022 and a floor of -$283.4 million in Q4 2025.
- Median Operating Income over the past 5 years was $143.2 million (2021), compared with a mean of $105.5 million.
- Biggest five-year swings in Operating Income: surged 79.18% in 2021 and later plummeted 226.15% in 2024.
- Charles River Laboratories International's Operating Income stood at $172.8 million in 2021, then dropped by 5.21% to $163.8 million in 2022, then decreased by 18.86% to $132.9 million in 2023, then plummeted by 226.15% to -$167.7 million in 2024, then crashed by 69.03% to -$283.4 million in 2025.
- The last three reported values for Operating Income were -$283.4 million (Q4 2025), $133.8 million (Q3 2025), and $100.1 million (Q2 2025) per Business Quant data.